EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials

Giovanni Maria Iannantuono, Elias Chandran, Charalampos S Floudas, Hyoyoung Choo-Wosoba, Gisela Butera, Mario Roselli, James L Gulley, Fatima Karzai

Cancer Treatment Reviews · 2023

DOI: 10.1016/j.ctrv.2023.102623 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Treatment Reviews, 2023. Verfasst von Giovanni Maria Iannantuono und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantMaleHumansImmune Checkpoint InhibitorsPatient SelectionProgression-Free Survival

Stichwörter der Autor:innen

EfficacyMeta-analysisPARP inhibitorsProstate cancerSafetySystematic review

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; Medical Oncology Unit, Department of Systems Medicine, University of…
  • Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
  • Division of Library Services, Office of Research Services, National Institutes of Health, Bethesda, MD, United States.
  • Medical Oncology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Iannantuono, G. M., Chandran, E., Floudas, C. S., Choo-Wosoba, H., Butera, G., Roselli, M., Gulley, J. L., & Karzai, F. (2023). Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2023.102623

Vancouver

Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, et al. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treatment Reviews. 2023. doi:10.1016/j.ctrv.2023.102623

BibTeX
@article{Iannantuono2023,
  author = {Iannantuono, Giovanni Maria and Chandran, Elias and Floudas, Charalampos S and Choo-Wosoba, Hyoyoung and Butera, Gisela and Roselli, Mario and Gulley, James L and Karzai, Fatima},
  title = {Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials},
  journal = {Cancer Treatment Reviews},
  year = {2023},
  doi = {10.1016/j.ctrv.2023.102623}
}
Kostenlos starten →